Skip to Content
MilliporeSigma
All Photos(3)

Documents

D134

Sigma-Aldrich

3,7-Dimethyl-1-propargylxanthine

≥98% (HPLC), powder

Synonym(s):

3,7-Dimethyl-1-(2-propynyl)xanthine, DMPX

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C10H10N4O2
CAS Number:
Molecular Weight:
218.21
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 15 mg/mL, clear

SMILES string

CN1C(=O)N(CC#C)C(=O)c2c1ncn2C

InChI

1S/C10H10N4O2/c1-4-5-14-9(15)7-8(11-6-12(7)2)13(3)10(14)16/h1,6H,5H2,2-3H3

InChI key

IORPOFJLSIHJOG-UHFFFAOYSA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

Application

3,7-Dimethyl-1-propargylxanthine (DMPX) has been used as an A2 -adenosine receptor (AR) antagonist:
  • to study its effects on potential modulation of motor output elicited by epidural spinal stimulation (ESS)
  • to study the role of A2a receptor in elevating cyclic adenosine monophosphate (cAMP) levels
  • to study its effects on the cell viability of human gastric cancer cell line

Biochem/physiol Actions

3,7-Dimethyl-1-propargylxanthine (DMPX) is a caffeine analog and A2-selective adenosine receptor (AR) antagonist.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Gloves


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ming Yang et al.
Naunyn-Schmiedeberg's archives of pharmacology, 375(2), 133-144 (2007-02-21)
Antagonists of adenosine A2A receptors (A2A -antagonists) with different chemical structures have been developed by several pharmaceutical companies for the potential treatment of Parkinson's disease. Pharmacological characterization of these antagonists was incomplete, and different assay conditions were used in different
Hanjeong Harvey et al.
Journal of bacteriology, 191(21), 6513-6524 (2009-09-01)
PilA, the major pilin subunit of Pseudomonas aeruginosa type IV pili (T4P), is a principal structural component. PilA has a conserved C-terminal disulfide-bonded loop (DSL) that has been implicated as the pilus adhesinotope. Structural studies have suggested that DSL is
Gabriele Pizzino et al.
Frontiers in pharmacology, 8, 558-558 (2017-09-21)
Glucocorticoid-induced osteoporosis (GIO) is a secondary cause of bone loss. Bisphosphonates approved for GIO, might induce jaw osteonecrosis; thus additional therapeutics are required. Adenosine receptor agonists are positive regulators of bone remodeling, thus the efficacy of adenosine receptor stimulation for
Annika Thorsell et al.
Alcoholism, clinical and experimental research, 31(8), 1302-1307 (2007-06-07)
It has been suggested that the reinforcing properties of ethanol are in part mediated via an A2 activation of cAMP/PKA signaling in the nucleus accumbens, predicting that administration of an A2a antagonist might reduce ethanol reward and consumption. We therefore
Maria Grazia Zizzo et al.
British journal of pharmacology, 148(7), 956-963 (2006-07-19)
The aims of the present study were firstly, to characterize pharmacologically the subtypes of P(1) purinoreceptors involved in the inhibitory effects induced by exogenous adenosine in longitudinal smooth muscle of mouse colon, and secondly, to examine differences in the function

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service